Pharvaris Reports Financial Results and Business Updates
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company, recently provided important updates on their business progress and key financial performances in the realm of treating bradykinin-mediated diseases, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). With their innovative approach, Pharvaris is working towards addressing significant unmet medical needs.
Clinical Trial Progress
The company is eagerly awaiting the topline data from their pivotal Phase 3 study, RAPIDe-3. This study investigates the immediate-release capsule of deucrictibant designed for the on-demand treatment of HAE attacks. Expected in the fourth quarter of 2025, this data readout is anticipated to be a crucial milestone for Pharvaris and could significantly influence treatment options for HAE patients.
Enrollment and Ongoing Studies
Furthermore, enrollment in a second pivotal Phase 3 study, CHAPTER-3, is proceeding as planned. This study focuses on the extended-release tablet formulation of deucrictibant and targets patients for prophylaxis against HAE attacks. Pharvaris expects to share topline data from this study in the second half of 2026. Alongside this, the company has also initiated the CREAATE study, which aims to evaluate deucrictibant for both prophylactic and on-demand treatments of AAE-C1INH attacks.
Recent Data Presentations
At recent medical congresses, Pharvaris shared valuable data, including findings from the open-label extension phase of their Phase 2 CHAPTER-1 study. These results reinforce deucrictibant's potential to stand out due to its distinctive efficacy and safety profile, crucial for patient treatment outcomes.
Financial Performance Overview
Pharvaris reported a robust financial position with cash and cash equivalents amounting to €329 million as of the third quarter of 2025. This figure indicates a solid foundation for their ongoing projects, compared to €281 million at the end of the previous year. The company is well-positioned financially to guide their projects well into the first half of 2027, ensuring they can navigate through critical development phases successfully.
Research and Development Investment
During this third quarter, Pharvaris invested significantly in their Research and Development (R&D) efforts, which reached €29.8 million. This reflects their ongoing commitment to advancement in treatment methodologies. Meanwhile, General and Administrative (G&A) expenses decreased to €9.8 million during this same period, showcasing efficient management of resources.
Loss Per Share Analysis
The company reported a loss of €37.1 million for the quarter, resulting in a basic and diluted loss per share of €0.60. Although this is a decrease from the previous year's loss per share of €0.77, it highlights the ongoing financial challenges typical for companies engaged in extensive clinical trials.
About Deucrictibant and Its Potential
Deucrictibant, the focus of Pharvaris's ongoing research, is a novel and powerful oral small-molecule bradykinin B2 receptor antagonist. It is under clinical evaluation for its potential to prevent bradykinin-mediated angioedema attacks and treats symptoms when they arise by obstructing bradykinin signaling through the B2 receptor. Pharvaris is championing two formulations of deucrictibant for oral use: an extended-release tablet for sustained efficacy and an immediate-release capsule for rapid effects.
Commitment to Innovation
Pharvaris emphasizes its mission to provide effective and convenient therapies. The aim is to deliver injectable-like efficacy with the convenience of oral medication to combat bradykinin-mediated angioedema effectively. With positive outcomes in their Phase 2 trials for both prophylaxis and on-demand treatments, the company continues to aim high with its innovative solutions.
Frequently Asked Questions
What are the recent developments at Pharvaris?
Pharvaris has shared updates regarding their clinical trials for deucrictibant and reported significant financial results, indicating a strong position moving forward.
What is deucrictibant?
Deucrictibant is a bradykinin B2 receptor antagonist under investigation for treating HAE and AAE-C1INH, offered in both immediate and extended-release formulations.
What were Pharvaris's financial results for the third quarter of 2025?
Pharvaris reported cash and equivalents of €329 million, with R&D expenses of €29.8 million and a quarterly loss of €37.1 million.
When is the data from the RAPIDe-3 study expected?
The topline data from the RAPIDe-3 study is expected to be announced in the fourth quarter of 2025.
How does Pharvaris plan to impact bradykinin-mediated diseases?
Through innovative therapies like deucrictibant, Pharvaris intends to provide effective treatments, improving the lives of those affected by these diseases.
